Search
Displaying results 661 to 669 of 669.
Strengthening of Drug Bioinformatics at the Saarbrücken Site
With additional funding of €100,000, the Klaus Faber Foundation supports Kalinina's project "bioINFpro," which aims to expand drug research through AI-based methods and develop new antibiotics against antibiotic-resistant bacteria. In doing so, the foundation makes a…
Four new junior research groups at the Helmholtz Centre for Infection Research
The ability to react to changes, to survive in existing habitats and to colonize new ones is a prerequisite for prevailing in the course of evolution. These principles of resilience and adaptability, especially in microorganisms, are at the heart of the HZI project…
Jump start for young female scientists
What sparked your interest in pharmaceutical research and how did you come to HIPS in particular? I find pharmaceutical research so exciting because it is so interdisciplinary and translational. When I decided to study pharmacy, I deliberately didn't want to focus on…
On the effectiveness of non-pharmaceutical interventions to combat pathogens
The novel coronavirus known as SARS-CoV-2 first appeared in the Chinese city of Wuhan at the end of 2019 and spread rapidly around the world. The first case in Germany was confirmed in January 2020. In early 2020, SARS-CoV-2 was identified as the cause of the infectious…
Personalised Immunotherapy
Our motivation is to address fundamental questions of human immunology and translate them into personalized therapies and diagnostics. Specifically, our laboratory discovers new applications of antibodies and B cells to treat and prevent human infectious diseases. Effective vaccines against some viruses that escape antibody responses remain elusive. To tackle this challenge, we develop methods to better understand B cell responses, the cells that produce antibodies. We design tailored vaccines and provide novel solutions for infection diagnostics. This Department is located at the Centre for Individualised Infection Medicine ( CiiM ).
Computational Biology for Individualised Medicine
Infections are among the biggest threats to health and the most significant causes of death worldwide. Our aim is to reveal the host genetic risk factors and their downstream molecular pathways, which are crucial to make progress in understanding and treating infectious diseases in an individualised manner as well as to improve the identification of patients at risk. The department is part of the developing CiiM and currently housed at the TWINCORE in Hannover.
Dynamics of Respiratory Infections
Several chronic inflammatory diseases of the lung have been recently associated with alterations in the composition of the airway microbiome. Moreover, the lung microbiota can be classified according to its predominance either of proinflammatory bacteria, such as strains from the genera S taphylococcus, Pseudomonas , and Haemophilus or of low-stimulatory bacteria from genera like Prevotella, Streptococcus , and Veillonella . Moreover, it is already known that the commensal lung microbiota can influence host immune system activation by producing numerous structural ligands and metabolites such as lipopolysaccharide, peptidoglycan, and secondary metabolites. However, the interaction between the lung microbiota and the airway epithelium, as well as their interactions with pulmonary pathogens, are not well understoo
